Literature DB >> 6329734

The gene structure of human anti-haemophilic factor IX.

D S Anson, K H Choo, D J Rees, F Giannelli, K Gould, J A Huddleston, G G Brownlee.   

Abstract

The mRNA sequence of the human intrinsic clotting factor IX (Christmas factor) has been completed and is 2802 residues long, including a 29 residue long 5' non-coding and a 1390 residue long 3' non-coding region, but excluding the poly(A) tail. The factor IX gene is approximately 34 kb long and we define, by the sequencing of 5280 residues, the presumed promoter region, all eight exons, and some intron and flanking sequence. Introns account for 92% of the gene length and the longest is estimated to be 10 100 residues. Exons conform roughly to previously designated protein regions, but the catalytic region of the protein is coded by two separate exons. This differs from the arrangement in the other characterized serine protease genes which are further subdivided in this region.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6329734      PMCID: PMC557470          DOI: 10.1002/j.1460-2075.1984.tb01926.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  40 in total

1.  Colony hybridization: a method for the isolation of cloned DNAs that contain a specific gene.

Authors:  M Grunstein; D S Hogness
Journal:  Proc Natl Acad Sci U S A       Date:  1975-10       Impact factor: 11.205

2.  Sizing and mapping of early adenovirus mRNAs by gel electrophoresis of S1 endonuclease-digested hybrids.

Authors:  A J Berk; P A Sharp
Journal:  Cell       Date:  1977-11       Impact factor: 41.582

3.  Screening lambdagt recombinant clones by hybridization to single plaques in situ.

Authors:  W D Benton; R W Davis
Journal:  Science       Date:  1977-04-08       Impact factor: 47.728

4.  3' non-coding region sequences in eukaryotic messenger RNA.

Authors:  N J Proudfoot; G G Brownlee
Journal:  Nature       Date:  1976-09-16       Impact factor: 49.962

5.  The nucleotide sequence of the initiation and termination sites for ribosomal RNA transcription in X. laevis.

Authors:  B Sollner-Webb; R H Reeder
Journal:  Cell       Date:  1979-10       Impact factor: 41.582

6.  AUG is the only recognisable signal sequence in the 5' non-coding regions of eukaryotic mRNA.

Authors:  F E Baralle; G G Brownlee
Journal:  Nature       Date:  1978-07-06       Impact factor: 49.962

7.  Messenger RNA for the Ad2 DNA binding protein: DNA sequences encoding the first leader and heterogenity at the mRNA 5' end.

Authors:  C C Baker; J Herisse; G Courtois; F Galibert; E Ziff
Journal:  Cell       Date:  1979-10       Impact factor: 41.582

8.  The isolation and characterization of linked delta- and beta-globin genes from a cloned library of human DNA.

Authors:  R M Lawn; E F Fritsch; R C Parker; G Blake; T Maniatis
Journal:  Cell       Date:  1978-12       Impact factor: 41.582

9.  Complete nucleotide sequence of the 5' noncoding region of human alpha-and beta-globin mRNA.

Authors:  F Baralle
Journal:  Cell       Date:  1977-12       Impact factor: 41.582

10.  Synthesis of double-stranded DNA complementary to lysozyme, ovomucoid, and ovalbumin mRNAs. Optimization for full length second strand synthesis by Escherichia coli DNA polymerase I.

Authors:  M P Wickens; G N Buell; R T Schimke
Journal:  J Biol Chem       Date:  1978-04-10       Impact factor: 5.157

View more
  113 in total

1.  A new strategy for the genetic counselling of diseases of marked mutational heterogeneity: haemophilia B as a model.

Authors:  F Giannelli; S Saad; A J Montandon; D R Bentley; P M Green
Journal:  J Med Genet       Date:  1992-09       Impact factor: 6.318

2.  A rapid test for V(D)J recombinase activity.

Authors:  S Kallenbach; M Goodhardt; F Rougeon
Journal:  Nucleic Acids Res       Date:  1990-11-25       Impact factor: 16.971

3.  Comparative sequence analysis of mammalian factor IX promoters.

Authors:  C P Pang; M Crossley; G Kent; G G Brownlee
Journal:  Nucleic Acids Res       Date:  1990-11-25       Impact factor: 16.971

4.  Duplications of the X chromosome in males: evidence that most parts of the X chromosome can be active in two copies.

Authors:  M Schmidt; D Du Sart; P Kalitsis; M Leversha; S Dale; L Sheffield; D Toniolo
Journal:  Hum Genet       Date:  1991-03       Impact factor: 4.132

5.  Hemophilia B (factor IXSeattle 2) due to a single nucleotide deletion in the gene for factor IX.

Authors:  B G Schach; S Yoshitake; E W Davie
Journal:  J Clin Invest       Date:  1987-10       Impact factor: 14.808

6.  Activation of Lyt-2 associated with distant upstream insertion of an SL3-3 provirus.

Authors:  D S Anson; K Clarkin; R Hyman
Journal:  Immunogenetics       Date:  1992       Impact factor: 2.846

7.  Assessment of the F9 genotype-specific FIX inhibitor risks and characterisation of 10 novel severe F9 defects in the first molecular series of Argentinian patients with haemophilia B.

Authors:  Claudia Pamela Radic; Liliana Carmen Rossetti; Miguel Martín Abelleyro; Miguel Candela; Raúl Pérez Bianco; Miguel de Tezanos Pinto; Irene Beatriz Larripa; Anne Goodeve; Carlos Daniel De Brasi
Journal:  Thromb Haemost       Date:  2012-10-23       Impact factor: 5.249

8.  Fixing human factor IX (fIX): correction of a cryptic RNA splice enables the production of biologically active fIX in the mammary gland of transgenic mice.

Authors:  F Yull; G Harold; R Wallace; A Cowper; J Percy; I Cottingham; A J Clark
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

9.  Structural analysis of the uEGF gene in the sea urchin strongylocentrotus purpuratus reveals more similarity to vertebrate than to invertebrate genes with EGF-like repeats.

Authors:  M G Delgadillo-Reynoso; D R Rollo; D A Hursh; R A Raff
Journal:  J Mol Evol       Date:  1989-10       Impact factor: 2.395

10.  Gene deletion in an Italian haemophilia B subject.

Authors:  F Bernardi; L del Senno; R Barbieri; D Buzzoni; R Gambari; G Marchetti; F Conconi; F Panicucci; M Positano; S Pitruzzello
Journal:  J Med Genet       Date:  1985-08       Impact factor: 6.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.